imaGenes GmbH Joins Roche NimbleGen's Certified Service Provider Program for ChIP-chip Analysis

Madison, WI, USA, (PresseBox) - Roche NimbleGen (SIX: RO, ROG; OTCQX: RHHBY) has announced that imaGenes GmbH, a Berlinbased genomics & proteomics specialist, has achieved status as a Certified Service Provider (CSP) of NimbleGen microarrays for Chromatin Immunoprecipitation (ChIPchip). imaGenes GmbH has passed a rigorous ChIPchip certification to officially become part of the Roche NimbleGen Certified Service Provider Program. As a CSP, they will be responsible for processing customer samples for DNAprotein interactions and chromatin structure. They have been certified at their lab in Berlin, Germany using the complete NimbleGen Dual-Color workflow which includes the highresolution MS 200 Microarray Scanner.

"The precision and flexibility of the NimbleGen Arrays was the decisive factor for imaGenes to immediately apply to Roche NimbleGen's Certified Service Provider Program and to use the technology in large scale for the "Epifood" project," says Dr. Steffen Hennig, Director Bioinformatics & Services at imaGenes. "The NimbleGen CSPstatus will position imaGenes at the international forefront of microarray application specialists".

"Roche NimbleGen is pleased to welcome imaGenes GmbH as our first global certified service provider for the ChIPchip application. imaGenes' microarray team has more than five years of experience with the technology of NimbleGen Arrays and their close ties with the former RZPD (German Science Center for Genome Research) and key opinion leaders brings an exceptional level of credibility to our core business of academic researchers. We anticipate that our relationship with imaGenes GmbH will further expand our business in the German market and fuel the basic research that is vital to the personalized healthcare pipeline," said Dr. Gerd Maass, CEO of Roche NimbleGen, Inc.

For more information about Roche NimbleGen, please visit

About imaGenes

imaGenes offers a complete portfolio of genomic research tools in addition to one of the most comprehensive collections of clones for mammalian and vertebrate genes in the world. imaGenes' research services feature a broad range of microarray and RTqPCR applications as well as next generation sequencing services on various platforms with collaborating partners. imaGenes places highvalue on creating modules which may be individually compiled to provide the optimum individual solution for each customer. As a result of their dedication to quality, imaGenes' quality management system has achieved international accreditation for compliance to the latest ISO 9001:2008 standards.

Roche Diagnostics Deutschland GmbH

Headquartered in Basel, Switzerland, Roche is a leader in researchfocused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in invitro diagnostics, tissuebased cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information:

Press releases you might also be interested in

Weitere Informationen zum Thema "Biotechnik":

Risiken bei IoT, KI sorgt für Vereinfachungen

Der Ma­chi­ne-Lear­ning-Ex­per­te Sp­lunk hat ei­ni­ge Vor­her­sa­gen für das kom­men­de Jahr ge­wagt. So sol­len et­wa Künst­li­che In­tel­li­genz (KI ) und ma­schi­nel­les Ler­nen den IT-Be­trieb deut­lich ve­r­ein­fa­chen.


Subscribe for news

The subscribtion service of the PresseBox informs you about press information of a certain topic by your choice at a choosen time. Please enter your email address to receive the email with the press releases.

An error occurred!

Thank you! You will receive a confirmation email within a few minutes.

I want to subscribe to the gratis press mail and have read and accepted the conditions.